Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
196
resultados
Última actualización
23/10/2026 [06:53:00]
Resultados 100 a 125 de 196
Resumen de: WO2026192089A1
The present invention relates to an artificial pancreas simulator and, more particularly, may comprise an infusion pump for administering insulin to a user, a blood glucose meter for measuring the user's blood glucose level at predetermined intervals, a user terminal for communicating with the infusion pump and the blood glucose meter, and an organ simulator for simulating bodily functions of the user related to changes in the user's blood glucose level.
Resumen de: US20260272336A1
A method for monitoring a subject’s blood glucose level, comprising: receiving a voiceprint from the subject; correlating the received voiceprint to a determined blood glucose level for the subject, using a predefined correlation model; determining, by comparing the determined blood glucose level to a predetermined acceptable blood glucose level range for the subject, whether the determined blood glucose level is outside the predetermined acceptable blood glucose level range for the subject; and generating an alert when the determined blood glucose level is outside the predetermined acceptable blood glucose level range for the subject.
Resumen de: WO2026193386A1
Systems and methods for estimating and tracking blood glucose levels are provided. A method includes receiving, from a sensor, a plurality of photoplethysmography (PPG) signals, deriving an oxygenated hemoglobin concentration signal and a deoxygenated hemoglobin concentration signal from the PPG signals, determining a phase relationship between the oxygenated hemoglobin concentration signal and the deoxygenated hemoglobin concentration signal, generating a glycemic pointer based at least in part on the phase relationship, and generating a first blood glucose level based on the glycemic pointer.
Resumen de: WO2026192544A1
The invention is a smart medical monitoring wristband developed for use in the healthcare sector. The wristband detects health parameters such as blood pressure, heart rate, oxygen saturation, body temperature, ECG, and blood sugar, and provides real-time remote access to this data. The wristband facilitates easy access to patients for healthcare professionals while enhancing patient comfort by providing music, games, and educational content. Additionally, it increases the number of patients under supervision through an emergency call button and GPS tracking system. Using AI-powered data analysis, it detects abnormal health conditions and automatically notifies the healthcare team. With its lightweight and ergonomic design prioritizing patient comfort, the device can be used securely with encrypted data.
Resumen de: US20260279537A1
Adaptive on board estimation of exogenous pharmacon responsive to transient (i.e., impermanent) physiological effects is provided. Dynamically estimating an equivalent amount of an exogenous pharmacon on board (XOB), such as insulin and/or carbohydrates, left in the subject, is based on predictions of glucose time-series data. These estimated values, such as insulin on board (IOB), are useful for diabetes management software, including decision support and/or artificial pancreas (AP) algorithms, for example.
Resumen de: US20260272337A1
The present disclosure relates to a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device is produced in a state in which a body attachment unit has been assembled inside an applicator, so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body only by simply activating the applicator. Particularly, the present invention provides a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device: includes a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use thereof, without additional work for connecting a separate transmitter, and easier maintenance; and is activated by a user's operation after the body attachment unit is attached to the body, so as to enable the operation start time to be adjusted to an appropriate time according to user's needs, and to enable the operation to start in a stabilized state so that blood glucose can be measured more accurately.
Resumen de: US20260272353A1
Systems and methods are described for monitoring blood glucose when driving. The methods may include receiving blood glucose input for a user over a time period, detecting one or more driving events associated with the user over the time period, correlating the blood glucose input with the one or more driving events; determining, based on the correlation, at least one pattern indicating a blood glucose status for the user, generating, based on the blood glucose status and a repository of user data, at least one insight or trend corresponding to the user, and causing presentation of the at least one insight or trend.
Resumen de: US20260272335A1
A customized wearable saliva biosensor system for continuous, real-time, in-situ monitoring of biochemical markers in human saliva. The system integrates a multi-gate organic electrochemical transistor biosensor employing an organic semiconductor channel with enzyme-functionalized gate electrodes, a compact wireless integrated circuit with Bluetooth data transmission, a power subsystem optionally incorporating piezoelectric and/or triboelectric nanogenerators, and a custom-fitted wearable substrate fabricated from a three-dimensional scan of the user's dental anatomy. The system is positioned within the oral cavity in proximity to the sublingual glands for direct detection of fresh saliva at the point of secretion. A differential measurement architecture comparing an enzyme gate to a control gate provides selective, real-time detection of target biomarkers including glucose, lactate, and uric acid. Measured data is wirelessly transmitted to a companion mobile application for display to the user.
Resumen de: EP4806354A2
0001 The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Resumen de: EP4807357A2
A method of making a nanoporous layer comprises providing a liquid composition comprising a surfactant and metal ions, adding a reducing agent to cause reduction of at least part of the metal ions to form nanoparticles, removing the surfactant to form a second colloid, adjusting a concentration of the nanoparticles to provide a colloid composition, dispensing the colloid composition over a substrate, and subjecting the dispensed colloid composition to drying to form the nanoporous layer.
Resumen de: EP4806508A2
A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.
Resumen de: EP4806351A2
0001 Embodiments of the invention provide compositions useful in implantable devices such as analyte sensors as well as methods for making and using such compositions and devices. In typical embodiments of the invention, the device is a glucose sensor comprising a polymeric composition disposed on a flexible assembly within the sensor that includes amounts of one or more immunosuppressant agents designed to provide such sensors with improved material properties such as enhanced biocompatibility.
Resumen de: WO2026188217A1
Described herein are compositions comprising Apolipoprotein E3 with the Christchurch mutation (e.g., R136S), or nucleic acids encoding the same, and methods of use thereof in disorders associated with aberrant angiogenesis, e.g., ocular neovascularization such as in wet age-related macular degeneration and diabetic retinopathy, or solid tumors, or bone diseases, e.g., osteoporosis including diabetic osteoporosis, or osteogenesis imperfecta.
Resumen de: WO2026187363A1
A method of multi-analyte analysis includes applying an electrical test sequence to a sample applied to a reagent in an electrochemical sensing device, generating a measurement of a primary analyte in the sample based on a response to the electrical test sequence, generating a classification of a secondary' analyte in the sample based on a least one feature extracted from the response to the electrical test sequence provided to a machine-learning model, the second analyte being different titan the first analyte, and generating at least one output corresponding to the measurement of the primary' analyte and the classification of the secondary analyte. Particular analytes of interest include glucose measurement and ketone classification.
Resumen de: US20260269465A1
0000 A medical device such as an automated medicament delivery device for automated administration of medicament to a user-body or an analyte sensor such as a continuous glucose monitor for detecting analyte levels in a user-body are disclosed. The automated medicament delivery device includes an antenna, a communication chip, and a gain control circuit. The communication chip configured for operation of the antenna in at least two selectable modes including a high-gain mode and a low-gain mode. The high-gain mode and the low-gain mode of the antenna at least partially based on a state of a gain control circuit operatively coupling the communication chip with the antenna. The antenna, utilizing the gain control circuit, operable in the low-gain mode during performance of a pairing operation with a separate device and operable in the high-gain mode during ongoing external communication.
Resumen de: WO2026187796A1
A sensor measures a physiological condition (e.g., glucose) of a user. The sensor also facilitates an assessment of a transient sensor signal skew that occurs to the sensor's signal. The transient sensor signal skew occurs as a result of an immune response or bleeding from the user's body, where the immune response or bleeding occurs in response to an insertion and/or subsequent retained presence of the sensor tail in the user's body. The sensor includes an optical sensor. As a result of an ointment being applied to a top layer of the user's skin, the skin becomes at least partially translucent. The optical sensor is directed towards the top layer of the skin onto which the ointment was applied. The optical sensor is structured to generate images of the translucent skin. The images reflect inflammation occurring under the skin. The transient sensor skew is based on the detected inflammation.
Resumen de: WO2026187966A1
A wearable smart insole for a user having foot having a planter arch and a medial plantar artery (MPA) along the plantar arch is provided. The insole has at least one optical sensor disposed in the insole along the MPA, a power handling circuit, an energy storage module operatively coupled with the power handing circuit to provide power to the optical sensor. The optical sensor is disposed along the MPA. in the insole and provides a signal for obtaining heart rate data, blood oxygen saturation data and blood glucose measurements. Two optical sensors may be provided along the MPA to provide signals for calculating blood pressure. A third optical sensor may be provided along the lateral plantar artery to provide signals to detect diabetes or arterial disease.
Resumen de: WO2026187690A1
The present disclosure generally relates to cell therapies and related methods, kits, assays, tests and devices for treatment of diabetes, including Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D), and other conditions characterized by insulin deficiency.
Resumen de: WO2026186968A1
The present invention relates to a composition for restoring pancreatic beta-cell function, the composition comprising intestinal organoid-derived exosomes. The intestinal organoid-derived exosomes according to the present invention have the effects of improving pancreatic-related markers and inflammation-related factors in a beta-cell damage model treated with palmitic acid, reducing the expression of oxidative stress-related factors, and restoring insulin secretion ability, and thus can be effectively used in the treatment of various diseases related to pancreatic beta-cell dysfunction, including diabetes.
Resumen de: WO2026184355A1
The present application relates to a method for online monitoring of vital sign parameters of a host and a multi-working-electrode system, which can improve the accuracy of glucose monitoring. The method comprises: using a first working electrode to acquire a first vital sign parameter of a host; using a second working electrode to acquire a second vital sign parameter of the host; and acquiring, on the basis of the first vital sign parameter and the second vital sign parameter, a target glucose concentration of the host. The first working electrode and the second working electrode are arranged on the same substrate, and can acquire the first vital sign parameter and the second vital sign parameter, respectively, at different depths of the host's tissue independently of each other. The two working electrodes can effectively determine analyte concentrations at different depths, which, combined with the vital sign parameters generated by the different working electrodes, can comprehensively provide more reliable continuous monitoring results, thereby improving the accuracy of monitoring.
Resumen de: AU2025232283A1
An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg/dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg/dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.
Resumen de: US20260269021A1
0000 A modular breath analysis system is disclosed for analyzing volatile organic compounds in exhaled breath and correlating measured compound profiles with physiological or pathological states of a subject. The system may include a breath sampling subsystem, a breath conditioning subsystem, a sensor array, and a processing subsystem configured to generate a volatile organic compound profile and apply a correlation model. In some embodiments, a base instrument is configured to receive interchangeable sensing modules through mechanical, fluidic, and electrical interfaces. The sensing modules may include gas sensors, flow-routing structures, filters, membranes, identifiers, calibration data, or combinations thereof. Different sensing modules may be configured for different volatile organic compound panels associated with metabolic conditions, blood glucose estimation, respiratory conditions, infectious diseases, cancer, or other physiological or pathological states.
Resumen de: WO2026184157A1
The present application relates to the technical field of computers, and specifically relates to a sensor, a measurement apparatus, a physiological parameter measurement method, and an electronic device. The sensor may be provided with at least a first working electrode and a second working electrode that are configured to acquire monitoring data. A first membrane layer attached to the surface of an enzyme layer of the first working electrode and a second membrane layer attached to the surface of an enzyme layer of the second working electrode may have different parameters, for example, the thickness of the second membrane layer is greater than the thickness of the first membrane layer, or the second membrane layer comprises a limiting layer, a protective layer formed of a soluble material attached to the surface of the limiting layer, etc., such that a first duration required for glucose to permeate through the first membrane layer is less than a second duration required for glucose to permeate through the second membrane layer, thereby enabling the second working electrode to be activated after the first working electrode has been used for a preset duration. In this way, the service life of the sensor, and that of the measurement apparatus, the electronic device, etc., using the sensor can be prolonged, which is beneficial for improving the user experience.
Resumen de: WO2026184101A1
A method and apparatus for real-time calculation of a gastric emptying rate of a patient. The method comprises: S1, using a fluorescence indicator method to determine a gastric emptying trend line representing a gastric emptying rate of a patient; S2, monitoring blood glucose of the patient in real time; and S3, correcting the gastric emptying rate of the patient in a personalized manner on the basis of a real-time blood glucose monitoring value of the patient. The apparatus comprises: a fluorescence measurement unit, configured to perform fluorescence measurement on a patient by using a fluorescence indicator method, to determine a gastric emptying trend line representing a gastric emptying rate of the patient; a blood glucose measurement unit, configured to monitor blood glucose of the patient in real time; and a calculation unit, configured to correct the gastric emptying rate of the patient in a personalized manner on the basis of a real-time blood glucose monitoring value of the patient, wherein the corrected gastric emptying rate can be calculated using a specific formula, and the specific formula incorporates a blood glucose rate-of-change coefficient for quantifying the impact of blood glucose changes on the gastric emptying rate, as well as the rate of change of blood glucose.
Nº publicación: US20260263559A1 10/09/2026
Solicitante:
WAKE FOREST UNIV HEALTH SCIENCES [US]
Wake Forest University Health Sciences
Resumen de: US20260263559A1
0000 Described herein are compositions comprising a combination of active agents, such as recombinant fibroblast growth factor-7 (FGF-7), recombinant follistatin, recombinant interleukin-6 (IL-6), recombinant transforming growth factor beta-1 (TGFβ-1), recombinant urokinase receptor (uPAR), and a carrier, which compositions may further comprise recombinant angiopoietin-1 (ANG-1), recombinant hepatocyte growth factor (HGF), recombinant insulin, and/or recombinant vascular endothelial growth factor (VEGF). Also provided herein are methods of treating wounds, accelerating healing of a wound, accelerating angiogenesis, and/or reducing scarring, as well as methods for culturing cells in vitro, and for cell delivery in vivo, using compositions of the present invention.
BOPI
Sede Electrónica
